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Abstract 
 
Choroideremia (CHM) is an X-linked chorioretinal dystrophy that is caused by 
mutations within a single gene, CHM. Currently no effective treatment exists for these 
patients. Since over 30% of patients harbour nonsense mutations in CHM, nonsense 
suppression therapy using translational readthrough inducing drugs (TRIDs) may 
provide functional rescue of REP1, thus attenuating progressive sight loss. Here, we 
employed two CHM model systems to systematically test the efficacy and safety of 
ataluren (PTC124) and its novel analog PTC-414: 1) the chmru848 zebrafish, the only 
nonsense mutation animal model of CHM harbouring a TAA nonsense mutation, and 
2) a primary human fibroblast cell line from a CHM patient harbouring a TAG 
nonsense mutation. PTC124 or PTC-414 treatment of chmru848 embryos led to a ~2.0 
fold increase in survival, prevented the onset of retinal degeneration with reduced 
oxidative stress and apoptosis, increased rep1 protein by 23.1% (PTC124) and 17.2% 
(PTC-414) and restored biochemical function as confirmed through in vitro 
prenylation assays (98 ± 2% [PTC124] and 68 ± 5% [PTC-414]). In CHMY42X/y 
fibroblasts, there was a recovery of prenylation activity following treatment with 
either PTC124 (42 ± 5%) or PTC-414 (36 ± 11%), although an increase in REP1 
protein was not detected in these cells, in contrast to the zebrafish model. This 
comprehensive study on the use of PTC124 and PTC-414 as successful nonsense 
suppression agents for the treatment of CHM highlights the translational potential of 
these drugs for inherited retinal disease. 
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Introduction 
 
Choroideremia (CHM) is an X-linked recessive inherited chorioretinal dystrophy 
caused by mutations in the CHM gene, that spans a genomic sequence of ~150 kb on 
chromosome Xq21.2, containing 15 exons and encoding a ubiquitously expressed 
protein of 653 amino acids; Rab Escort Protein 1 (REP1). REP1 is an essential 
component of the catalytic Rab geranyl-geranyl transferase (RGGTase) II complex, 
and is involved in lipid modification (prenylation) of Rab proteins and facilitates their 
intracellular membrane transport trafficking by binding to the hydrophobic 
prenylation motifs at the C termini.(1) There are over 50 Rab proteins, present in all 
cells. Within the retina, they act to transport melanosomes within the retinal pigment 
epithelium (RPE) and assist phagocytosis of disc membranes shed from the outer 
segments. There have been over 200 unique mutations involving CHM reported in the 
Human Gene Mutation Database (HGMD®) and characterisation of the mutation 
spectrum reveals 30% are nonsense mutations resulting in premature termination 
codons (PTCs).(2) Humans have two REP isoforms, REP1 and REP2 (encoded by the 
retrogene choroideremia-like, CHML, located on chromosome 1), which share 75% 
amino acid identity, enabling Rabs to competitively bind to one or the other. 
However, a subset of Rabs have been found to be prenylated less efficiently by REP2 
than by REP1 i.e. Rab27a exhibits a 4-fold difference and Rab7 shows a >6-fold 
difference.(3) This has led to the proposal that loss of function CHM mutations reduce 
the amount of total REP activity, shifting prenylation towards REP2. In the retina, 
where there is active synthesis of multiple Rabs, competitive binding results in 
underprenylation of low affinity Rabs, such as Rab27a, resulting in a subsequent 
retinal degeneration.  
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Affected male patients typically develop early onset night blindness in childhood, 
followed by restriction of the peripheral visual field, and finally a decrease in central 
visual acuity, often leading to complete blindness during the 5-6th decade of life.(4) 
Female carriers may be asymptomatic, or display patchy areas of chorioretinal 
atrophy that represent clonal areas of the disease due to random X-inactivation. 
However, later in life, carrier females can often develop night blindness and field loss 
because of expanding areas of chorioretinal atrophy. 
 
In order to test the safety, efficacy and application of small molecule translational 
readthrough inducing drugs (TRIDs) for the potential treatment of inherited retinal 
disease, CHM was selected as a prototype given its causative preponderance of 
nonsense mutations. In this study we used two independent disease models of CHM. 
Firstly, human primary fibroblast cell line, derived from a CHM patient with a 
nonsense mutation resulting in absent REP1 and loss of prenylation function, 
therefore acting as a suitable cellular model for testing pharmacological therapies. 
Secondly, in order to study the effect of drug treatment on the entire retina, the in vivo 
chmru848 zebrafish was used. This is the only animal model of CHM with a nonsense 
mutation in the chm gene, resulting in a UAA nonsense codon p.Q32X  in exon 2.(5) 
Zebrafish possess only one rep isoform, which shares 55% homology with human 
REP1. The lack of a second rep isoform to compensate in tissues other than the eye, 
analogous to human REP2, leads to a multisystemic disease in zebrafish resulting in 
embryonic lethality by a mean 4.8 ± 1.0 days post fertilisation (dpf). The retinal 
degeneration is well-characterised with the first signs emerging as patchy areas of 
RPE hypertrophy and atrophy at 4.5 dpf followed by a widespread severe 
degeneration with loss of retinal lamination and high levels of cell death by 5 dpf. 
This is due to the loss of maternal rep1 mRNA and protein present in the yolk sac that 
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supports normal development up till 4 dpf.(5) Any therapy that can increase rep1 
protein will have a global effect on the fish without any confounding factors. This 
model has been successfully used previously to highlight the efficient readthrough of 
traditional aminoglycosides, paromomycin and gentamicin.(6) Using this model also 
allows other systemic drug side effects including oto- and renal toxicity to be 
investigated.  
 
Ataluren (PTC124) was discovered through high-throughput screens utilizing 
premature UGA luciferase (LUC) reporters in either stably transfected HEK293 cells 
or rabbit reticulocyte lysates. Chemical optimization of hit molecules using nonsense-
containing cell and animal models and pre-clincal safety assessments ultimately 
resulted in the selection of PTC124 as a clinical candidate. Further chemical 
optimization to increase plasma exposure and tissue penetration was performed using 
a similar screening tier as PTC124. Compounds that manifested increased 
readthrough activity at UGA, UAA and UAG codons with minimal cellular toxicity 
were characterized further for their relative potency, activity and pharmaceutical 
properties. These studies led to the identification of several lead compound classes 
that were further chemically optimized. PTC-414 was identified as a compound that 
maintained the favourable properties of PTC124, but improved the potency, 
pharmacokinetic properties and the readthrough at all three stop codons (Table 1). 
 
In this study we test these two small molecule TRIDs, PTC124 and PTC-414, to 
compare their level of translational readthrough in two independent in vitro and in 
vivo disease models of choroideremia.  
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Results 
 
Therapeutic dose of TRIDs for the chmru848 zebrafish model  
 
To determine the highest dose of drug that could be safely tolerated in zebrafish, we 
carried out survival experiments. The survival of wildtype (wt) embryos dosed 
continuously from 10 h post fertilization (hpf) (prior to eye development) with 
PTC124 and PTC-414 (0.025–50 µM) was measured at 6 days post fertilization (dpf) 
(Fig. 1A). Median lethal dose (LD50) was 15 µM for PTC124 and 4 µM for PTC-414. 
The potency of the gentamicin solution differed from previous experiments hence the 
dose response curve was repeated to determine the optimum dose, and was found to 
be 10 µM with a LD50 of 21 µM (Fig. 1A). Embryos treated with 10 µM gentamicin, 
10 µM PTC124 and 2 µM PTC-414 displayed 98.7 ± 1.3% survival rates (in line with 
natural survival rates of untreated wt embryos) at 6 dpf with normal gross 
morphology and retinal histology (Fig. 1B). There was no difference in gross 
behaviour between untreated and treated wt embryos, all demonstrating normal 
stereotyped motor behaviors that allow them to navigate their environment including 
slow and fast swimming bouts, with no signs of imbalance or lack of movement. 
Following single dose administration of 10 µM PTC124 and 2 µM PTC-414 to wt 
embryos at 10 hpf (20 embryos per group, with three biological replicates), the 
concentration of PTC124 and PTC-414 was measured at day 1, 3 and 6 (Fig. 1C). 
Both drugs reached a peak at day 3 with PTC124 reaching a mean of 29 ng/fish (0.1 
nmole/fish) and PTC-414 8.9 ng/fish (0.02 nmole/fish), both tapered off by day 6 
although the drugs were still detectable compared to undosed fish.  
 
Renal- and oto-toxic assays for TRIDs 
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Although PTC derivatives are unrelated to aminoglycosides, which cause significant 
renal and ototoxicity, these parameters were tested to complement the morphological, 
behavioural and retinal safety profile. Pronephric tubule filtration efficiency, as a 
measure of renal function, was tested by injecting rhodamine-labelled 10 kDa dextran 
into the pericardial sac of untreated and treated wt fish and measuring the transit of 
dye out of the circulation, which if normal occurs through the glomerulus with 
excretion in the urine (Fig. 2A, B). PTC124 (10 µM) showed no signs of toxicity with 
good filtration efficiency (37.6 ± 1.7%) comparable to wildtype levels (38.6 ± 3.2%). 
PTC-414 (2 µM) demonstrated a degree of renal dysfunction (68.8 ± 3.1%), which 
was significantly higher than PTC124 and wildtype fish (P<0.01), but not as severe as 
gentamicin (10 µM), where 94.7 ± 5.5% of the dye failed to be excreted by the 
embryos. 
 
The lateral line neuromast mechanosensory hair cells of larval zebrafish were used as 
an in vivo surrogate model of mammalian inner ear hair cells to test ototoxicity of 
PTC124 and PTC-414. Live embryos at 6 dpf were incubated with 4-Di-2-Asp, a 
fluorescent dye that is preferentially taken up by hair cells. Gentamicin is a known 
ototoxin and showed reduced staining and a statistically significant reduction in 
neuromast survival score of 0.5 ± 0.5, indicative of hair cell damage or loss (Fig. 2C, 
D). PTC124 (score 28.8 ± 3.8) and PTC-414 (score 30.4 ± 6.7) showed no significant 
reduction in the gross number of neuromasts relative to untreated larva.  
 
In order to view the structural integrity and number of hair cells in the neuromasts, 
immunostaining with anti-acetylated tubulin, which labels the kinocilia, and 
phalloidin labeling of the stereocilia bundles was performed in fixed wt larva 
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following drug exposure (Fig. 2D). We counted the hair cells in the opercular (OP) 
neuromast of 5 wt embryos from each treatment group, and found the mean number 
(± SD) of hair cells per neuromast at 6 dpf was 12.0 ± 3.5. This was in-line with 
previously published counts of 13.3 ± 2.94.(7) This was markedly reduced for 
gentamicin-treated fish (1.2 ± 1.0, p<0.01) compared to PTC124 (10.1 ± 3.6) and 
PTC-414-treated (9.4 ± 3.1) embryos. 
 
TRID treatment increases the survival of chmru848 mutants 
 
On the basis of the results in wt fish, the effect of each compound on survival in 
chmru848 mutants was determined following the administration of 10, 2 and 10 µM of 
PTC124, PTC-414 and gentamicin, respectively, at 10 hpf compared with untreated 
embryos (Fig. 3A). Untreated chmru848 mutants survived an average of 4.8 ± 1.2 days, 
whereas chmru848 embryos treated with PTC124 lived for 10.1 ± 1.6 days representing 
a 2.1-fold increase in survival. PTC-414 treated fish lived for 9.1 ± 1.7 days extending 
a 1.9-fold increase in survival, and gentamicin control fish lived for 8.2 ± 1.4 days 
with a 1.7 fold increase in survival. Treatment of chmru848 mutant embryos with either 
drug significantly increased their survival time (P<0.01) compared with untreated 
mutants; however, the difference between survival of gentamicin-treated and PTC 
derived-treatment groups was not significant. In order to confirm whether the 10 µM 
dose of PTC124 was optimum, chmru848 embryos were dosed with 5 and 15 µM 
concentrations, the survival dropped to 5.6 ± 0.1 days and 5.3 ± 0.6 days, 
respectively, there was no significant difference from undosed mutants (Fig. 3B). In 
addition, dosing of chmru848 embryos with 10 µM at 3 dpf did not improve their 
phenotype or their survival (6.0 ± 0.1 days). PTC-414 showed a narrow dose response 
with 32% lethality with 3 µM treatment at 10 hpf (Fig. 1A), and when dosed at 3 dpf 
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with 2 µM there was also no improvement in survival (5.6 ± 0.4 days). 
 
Effect of TRID treatment on chmru848 morphology and retinal histology 
 
Mutant chmru848 larvae at 6 dpf displayed characteristic systemic defects such as 
pericardial and abdominal oedema, shorter body length (mean 2.81 ± 0.25 mm), an 
uninflated swim bladder, persistent yolk sac and microphthalmia (mean 228 ± 10 µm) 
with irregular darker eye pigmentation due to reduced iridophore pigment cells (Fig. 
3C). Treatment with 10 µM PTC124 or 2 µM PTC-414 resulted in milder chmru848 
phenotypes at 6 dpf with reduced pericardial and abdominal oedema, significantly 
increased body length and larger eye diameter compared with untreated mutants 
(p>0.01, Fig. 3C-E). There was no significant difference between treated chmru848 and 
wt parameters (mean body length 3.85 ± 0.22 mm and mean eye diameter 310 ± 14 
µm). Importantly, a functional inflated swim bladder failed to develop in treated 
mutants and this consequently impaired proper feeding, leading to starvation, as was 
seen in our previous study with aminoglycosides.(6) 
 
Coronal sections of the chmru848 retina showed widespread degeneration with pyknotic 
cells (nuclear condensation appearing dark with overall loss of cytoplasm) throughout 
all layers of the retina, diminishing lamination, areas of RPE atrophy and hypertrophy 
and small cataractous lenses (Fig. 3A).(5) Treated chmru848 mutant retina at 6 dpf 
showed remarkable preservation of lamination including a regular RPE layer, absence 
of pyknotic cells and normal lens. The main difference between treated chmru848 
mutant and wt retina was notably thickened inner nuclear and ganglion cell layers 
(Fig. 3A). In addition, the ganglion cell layer was closely opposed to the lens in the 
treated mutants owing to ganglion cell proliferation. At 10 dpf, retinal sections 
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appeared similar to wt fish, although the ganglion cell layer and inner nuclear layer 
remained increased with a higher density of nuclei, and reduction of the vitreous 
cavity (Fig. 3D). There were early signs of RPE hypertrophy in the PTC-414 treated 
retina, but no gross signs of photoreceptor degeneration.  
 
Effect of TRID treatment on apoptotic cell death in zebrafish mutants 
 
TUNEL assays were performed on coronal retinal sections of wt, untreated and 
treated chmru848 embryos at 6 dpf to assess levels of cell death. In each mutant treated 
with either 10 µM PTC124 or 2 µM PTC-414 at 10 hpf (n=5 per group), apoptotic 
activity was significantly reduced to wildtype levels within the retina (p>0.01, Fig. 
3A, B), which may have accounted for the thicker nuclear layers. The gentamicin 
treated retina did however display slightly higher levels of cell death predominantly in 
the RPE, photoreceptor layer and around the lens but still remained significantly 
lower compared to untreated mutants.  
 
Oxidative stress in the chmru848 eye 
 
The superoxide-sensitive dye dihydroethidium (DHE) was used to semi-quantitatively 
evaluate the in situ generation of superoxide and thiobarbituric acid reactive 
substances as indicators of lipid peroxidation and oxidative stress in the eyes of wt 
and chmru848 treated and untreated embryos (Fig. 3A, C). In untreated chmru848 whole 
eyes, there were high levels of oxidative stress associated with the disease process 
itself (mean DHE fluorescence/eye 27.9 ± 1.1). Once dosed with PTC-derived small 
molecules, the reactive oxygen species (ROS) reduced significantly to wt levels 
(P<0.01). Gentamicin is known to cause oxidative stress and the mean DHE 
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fluorescence/eye was 12.1 ± 0.8 in wt embryos treated with 10 µM gentamicin.(8) But 
the generation of functional rep1 through its readthrough ability appears to have an 
overall treatment benefit, highlighted by the reduction of ROS in gentamicin treated 
mutants (mean DHE fluorescence/eye 17.4 ± 1.2) versus untreated chmru848, despite 
its toxic side effects. 
 
Quantitative RT-PCR 
 
Nonsense mediated decay (NMD) is a surveillance process that recognizes and 
selectively degrades PTC-containing mRNA. The level of NMD sensitivity is 
multifactorial resulting in a proportion of transcripts escaping the pathway. In order to 
detect the level of mRNA available for readthrough activity, quantitative RT-PCR 
was conducted using untreated chmru848 embryos, revealing transcripts reached a mean 
42 ± 6% of wildtype levels (Fig. 5A). When treated with PTC124, transcript levels 
rose to a mean 74 ± 9 %, however, a similar increase was not observed following 
PTC-414 treatment with levels remaining at 49 ± 3%.  
 
Patient CHMY42X/y fibroblasts were derived from a skin biopsy of a 25-year-old male. 
The nonsense mutation c.126C>G (p.Y42X, UAG) was confirmed in the fibroblasts 
by direct sequencing.  Untreated and treated CHMY42X/y patient fibroblasts were 
analyzed for levels of mRNA transcripts compared to male control wildtype 
fibroblasts. CHMY42X/y fibroblasts expressed a mean 13 ± 3% of wildtype mRNA 
levels, and this was comparable to PTC124 (22 ± 9%) and PTC-414 (16 ± 8%) treated 
CHMY42X/y patient fibroblasts (Fig. 5A). This is consistent with previous reports of 
PTC124 having no effect on NMD or other aspects of mRNA stability.(9, 10)  
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REP1 protein detection in chmru848 mutants and CHMY42X/y fibroblasts following TRID 
treatment 
 
To determine whether PTC124 and PTC-414 treatment increased rep1 protein 
expression, western blot analysis was undertaken on total zebrafish extracts from wt, 
untreated and drug-treated chmru848 mutants at 6 dpf. Untreated chm mutants at 6 dpf 
demonstrated levels of 14.7% rep1 protein expression relative to β-actin, and this 
source is attributed to residual maternal rep1 derived from the persistent yolk sac. 
This background maternal contribution was subtracted from the total REP1 detected 
from treated samples to quantify the amount of protein generated through 
readthrough.  PTC124 and PTC-414-treated chmru848 larvae at 6 dpf expressed a mean 
increase of 23.1% and 17.2% rep1 protein secondary to nonsense suppression, 
respectively, after deduction of background maternal contribution (Fig. 5B). Positive 
control gentamicin showed a 15.1% increase in rep1 protein, suggesting PTC124 has 
better readthrough efficiency.  
 
Male control WT fibroblasts and patient-derived CHMY42X/y fibroblasts treated with 50 
µM gentamicin, 40 µM PTC124, and 80 µM PTC-414 (concentrations correlated with 
the maximum prenylation rescue, see below) for a 24 hour period were analyzed for 
REP1 expression by western blotting. No REP1 was detectable by western blot in 
either the untreated or treated CHMY42X/y fibroblasts compared with controls (Fig. 6A). 
The mouse monoclonal anti-REP-1 antibody, clone 2F1 used in this study to detect 
human REP1 has been extensively characterized and known to detect the 415 C-
terminal amino acids of REP1.(11, 12) 
 
In vitro prenylation assay 
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To determine whether the biochemical defect causing CHM was rescued by TRID 
readthrough, the size of the unprenylated Rab pool was measured using an in vitro 
prenylation assay. Recombinant Rab geranylgeranyl transferase, REP1, and geranyl 
pyrophosphate (the biotinylated prenyl donor) were combined with the lysate of 
wildtype or CHMY42X/y fibroblasts, and whole wildtype or chmru848 mutant zebrafish. 
Any unprenylated Rabs available for prenylation, would be labeled with biotin 
through the prenyl donor and thus be detected by western blot analysis using 
horseradish peroxidase–conjugated streptavidin.(13) Under these conditions, the 
semi-quantification of three experiments showed the amount of biotinylated Rab 
proteins in chmru848 zebrafish extracts reached 100% compared with only 1% in wt 
extracts (Fig. 5C), and 100% in CHMY42X/y fibroblasts compared to <1% in wildtype 
cells (Fig. 6B-D). Thus, a high level of biotinylated Rabs in chmru848 mutant and 
CHMY42X/y fibroblast extracts reflects no REP1 activity in each model system. In fish 
treated with 10 µM PTC124 or 2 µM PTC-414, the unprenylated Rab pool was 
reduced by 98 ± 2% and 68 ± 5%, respectively (Fig. 5C). This demonstrated that 
treatment with both TRIDs resulted in a significantly higher level of functional rep1 
activity in vivo, compared with untreated fish (p<0.01). In the CHMY42X/y fibroblasts 
treated with 50 µM gentamicin (Fig. 6B), 40 µM PTC124 (Fig. 6C) or 80 µM PTC-
414 (Fig. 6D) there was a rescue of prenylation function with 28 ± 10%, 42 ± 5% and 
36 ± 11% reduction in unprenylated Rab accumulation, respectively. 
 
Discussion 
 
In this study, we have demonstrated that small molecule drugs PTC124 and its 
derivative PTC-414 can successfully readthrough CHM-related nonsense mutations 
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resulting in functional rescue of REP1 in human derived CHM fibroblasts and arrest 
of the disease phenotype associated with an overall increase in survival in chmru848 
zebrafish. This study provides further evidence that TRIDs have the potential to 
restore functional protein in patients with retinal disorders and should be translated to 
clinical trials for those with nonsense-mediated genetic eye disease.  
 
Ataluren (PTC124™) is approved for nonsense mutation Duchenne Muscular 
Dystrophy (nmDMD) in the EU, exhibiting a good safety profile and clinical benefit 
in the six-minute walk test in patients when taken orally.(14) This study confirmed 
that both PTC-derived drugs have a better safety profile than traditional 
aminoglycosides. PTC124 was found to be safe and tolerable with negligible effect on 
renal function and neuromast survival, although PTC-414 did exhibit limited renal 
toxicity in the zebrafish model.  
 
Treatment of chmru848 embryos was optimal at 10 hpf, similar to that in our previous 
published study examining the translational readthrough effects of gentamicin and 
paromomycin in ocular coloboma and chmru848 zebrafish models.(6) Dosing with 10 
µM PTC124 at 3 dpf, prior to the onset of retinal degeneration did not aid the overall 
survival of the fish, the outcome was found not to be statistically significant. In 
addition, the dose concentration of PTC124 followed a bell shaped curve in the 
chmru848 mutants treated at 10 hpf, with reduced survival at 5 and 15 µM, comparable 
to undosed embryos. Studies of aminoglycosides have also manifested bell-shaped 
dose-response relationships in cells (15-17) and mice (18), and with PTC124 in 
patients with DMD (19) and the corresponding zebrafish model.(20)  
 
The mean baseline levels of mRNA transcripts in chmru848 embryos was 42%, 
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indicating a large proportion were escaping NMD, although there is likely to be a 
significant contribution of normal transcripts from the residual maternal yolk sac at 
this developmental stage, highlighted by a baseline of 14.7% rep1 protein at 6 dpf in 
the western blot (Fig. 5B). However, the sensitivity of NMD is multifactorial and a 
number of molecular mechanisms exist to either trigger or inhibit this process.(21, 22) 
The AUG-proximity effect and translation re-initiation act to suppress NMD.(23-25) 
This has been demonstrated with human α-globin transcripts, where the boundary of 
the AUG-proximity effect for NMD resistance resides between codons 30-32, 
resulting in steady-state levels of between 57-95% of wildtype mRNA levels.(23) 
Nonsense mutations between codons 32 and 70 in the first half of exon 2 of the 
human α-globin gene, produced transcript levels ranging from 27% to 40%, 
indicating full sensitivity to NMD. The AUG-proximity effect is primarily due to the 
mRNA circulization structure and a short open reading frame (ORF). The nonsense 
mutation in the chmru848 zebrafish model is situated within codon 32 of exon 2, 
whereas the CHM patient’s variant is found within codon 42 of exon 3. Therefore, it 
is plausible that due to the position of the AUG, an inhibitory NMD effect would 
account for the higher levels of zebrafish chm transcripts. Due to the downstream 
AUG position in the CHM patient, mRNA transcripts are likely to be susceptible to 
NMD resulting in the lower baseline levels seen in the fibroblasts.  
 
Translation re-initiation can occur in some genes if an AUG is present 3’ to the PTC, 
but is dependent on its position, for example with human α-globin gene, if the AUG 
is present at codon 32 following a 5’ PTC, this results in high levels of translation re-
initiation.(23) In contrast, an AUG present at codon 55 in the human ß-globin gene 
failed to inactivate this process. It is unlikely that translation re-initiation will 
contribute to mRNA levels in CHM, as a second AUG is not present until codon 149 
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in the chm transcript and codon 182 in humans.  
 
Another potential mechanism affecting the levels of mRNA is the presence of an 
upstream ORF (uORF). This is a regulatory element characterized by an initiation 
codon in the 5' UTR that is out-of-frame with the main coding sequence and has a 
resulting termination codon located upstream or downstream of the main AUG.(27) 
Bioinformatic studies have shown that approximately 49% of the human 
transcriptome contains uORFs, and these significantly reduce protein expression 
levels by reducing the efficiency of translation initiation of the main ORF or trigger 
NMD.(28-31) The human CHM transcript has an uORF spanning 18 codons between 
-20 from the main AUG and a downstream termination codon (TGA) at +32. There is 
no uORF in the zebrafish chm gene.  It has been suggested that uORF can trigger 
NMD as the uORF termination codon can be recognized as premature. Again, due to 
the circulization of the mRNA transcript, position of the termination codon, and 
length of the uORF, transcripts with longer uORFs are considered NMD-sensitive 
compared to those that are shorter.(27) The minimum size of the uORF has not yet 
been defined in mammalian cells, however studies in plants suggest 35 codons is the 
threshold.(32) This suggests that the human CHM transcripts would be unaffected by 
this particular NMD trigger. Further work is required to fully understand the NMD 
pathway response in CHM disease models. By investigating these mechanisms on 
different nonsense mutations, it may provide a prognostic factor linking treatment 
response to baseline transcript levels in affected patients. Based on the levels of 
mRNA transcripts in the disease models, it would be prudent to consider a 
combination treatment using an NMD inhibitor such as amlexanox together with a 
TRID to enhance the available substrate for translational readthrough.(26)  
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Previous reports have found that PTC124 does not have any effect on NMD or other 
aspects of mRNA stability.(9, 10) However, from the quantitative RT-PCR results we 
see higher levels of transcripts in PTC124 dosed chmru848 zebrafish compared to the 
undosed mutants. No significant difference was seen between untreated and treated 
human CHMY42X/y fibroblasts, showing a more consistent result with previous 
studies.(33) The exact molecular mechanism of PTC-derived drugs remains unknown, 
as does nonsense surveillance, both may have differing effects across species that 
could account for this variation. Nonetheless, having higher baseline mRNA levels is 
undoubtedly beneficial for translational readthrough therapy as increased substrate 
will lead to increased protein production.(26, 34) From our western blot, rep1 protein 
levels were detectable in zebrafish extracts but not in human CHM fibroblasts. The 
human CHM uORF may have impacted on protein expression, as uORFs have been 
found to lower protein levels by 30-80%.(29) Despite this, a marginal amount of 
REP1, which was not sensitive to detection, must have been produced, as a functional 
response to treatment with gentamicin, PTC124 and PTC-414 was seen through the 
biochemical prenylation assay. Others have documented that some readthrough agents 
have functional benefit in cell or animal systems, but full-length protein cannot be 
detected due to lack of sensitivity of protein detection assays.(35, 36) The proportion 
of functional rescue was between 1.5-1.7 fold greater than untreated CHMY42X/y 
fibroblasts. The zebrafish showed 100% prenylation of Rabs with a corresponding 17-
23% increase in rep1.  
 
The principle behind translational readthrough therapy is underpinned by mispairing 
of a near-cognate aminoacyl-tRNA with a stop codon. This occurs at a basal rate of 
0.001-0.1% at normal stop codons,(37) and 0.01 to 1% at PTCs.(38-40) One study 
investigated which amino acids were incorporated into an in-frame UAG PTC near 
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the 5′-end of a ß-galactosidase reporter gene.(41) The resulting full-length protein 
was subjected to N-terminal sequencing, and revealed that lysine (AAG), tryptophan 
(UGG), and tyrosine (UAU and UAC), were primarily inserted at the PTC. On the 
basis that near-cognate mispairing could occur at any of the three positions of the stop 
codon, predictions of seven amino acid combinations for a UAG stop codon, and six 
different amino acid codes could be incorporated at either the UAA or UGA 
codons.(42) In the case of our CHM patient with a p.Y42X (UAG), replacement with 
tyrosine would successfully restore wild-type protein. If an alternate amino acid is 
inserted to introduce a missense protein, this will have little effect on the severity of 
disease as no genotype-phenotype correlation has been found in CHM.(2, 43, 44) 
However, if increased levels of non-functional full-length protein were formed, the 
prenylation assay would not have shown any functional rescue.  
 
The results from this study show functional rescue in both zebrafish and human 
models of CHM, and therefore adds to the evidence that only a small increase in 
functional protein is enough to prevent the onset or halt/slow progression of recessive 
disease, notably in retinal degenerations.(6) CHM currently has no effective therapies 
available. The first Phase I-II viral gene therapy clinical trial involving 6 patients with 
CHM was reported to be safe and well tolerated, with a greater than 2- and 4-line 
improvement in visual acuity in 2 patients following treatment with the AAV2-REP1 
vector.(45) Phase II trials are being planned. TRIDs provide strong potential 
candidates for a successful pharmacological genetic treatment of CHM. As noted 
earlier, PTC124 is approved for use in nmDMD in the EU and is in phase III clinical 
trials for CF (ClinicalTrials.gov Identifier: NCT02107859). Preclinical studies have 
demonstrated efficacy of PTC124 in a wide range of nonsense mutation- mediated 
diseases.  Previous work by Goldmann and colleagues showed successful readthrough 
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of the p.R31X (UGA) nonsense mutation in USH1C, known to cause Usher syndrome 
type IC, with PTC124 in  cell culture, organotypic retina cultures, and in vivo 
mice.(46) Schwarz and colleagues showed production of up to 20% of endogenous, 
full-length RP2 protein in patient induced pluripotent stem cell (iPSC) derived RPE 
cells with a p.R120X (UGA) stop codon mutation causing X-linked retinitis 
pigmentosa.(33) In the aniridia Pax6Sey+/- mouse model with a p.G194X (UGA) 
nonsense mutation, Gregory-Evans and colleagues showed marked developmental 
plasticity with post-natal reversal of corneal, lens, and retinal malformation defects 
following treatment with PTC124.(47)  
 
The majority of ocular studies investigating the efficacy of TRIDs were tested on 
cellular and animal disease models caused by UGA mutations, although UAA 
nonsense mutations in dystrophin in zebrafish and mice respond to PTC124 treatment. 
In our paper, we have tested two CHM models with different stop mutations, firstly 
human CHMY42X/y fibroblasts with a UAG, and secondly, the chmru848 zebrafish with a 
UAA. PTC-414 was designed to have better potency and readthrough of UAA 
compounds, consistent with the lower dose of compound associated with an effect. It 
is important to pursue lead compounds in order to generate an armory of novel small 
molecule drugs that may differ in their pharmaceutical properties and therefore be 
preferable for particular genetic conditions for clinical application. 
 
PTC124 and PTC-414 were detectable in the zebrafish following single 
administration up to day 6. In CHM, the neurosensory retina, RPE and 
choriocapillaris degenerate relatively independently,(4) this leads to a breakdown of 
the outer blood-retinal-barrier, and hence, should enable orally administered TRIDs to 
potentially reach the target disease cells.  This treatment would not be suitable for 
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individuals who have end-stage disease with extensive chorioretinal atrophy. 
Postmortem histological sections of a 30 year old patient with a p.R253X in exon 6 of 
the CHM gene suggested retinal degeneration was observed above either preserved or 
severely atrophic RPE and choriocapillaris. Patchy islands of relatively well-
preserved retinal architecture directly adjacent to areas of severe degeneration.(4) 
Administration of pharmaceutical agents where retinal cells are present albeit under 
stress, provides the opportunity for generation of functional protein which could help 
reduce secondary pathological effects like oxidative stress or postpone terminal cell 
death and improve overall health of the islands of residual retinal tissue.  
 
Interestingly, a recent paper suggests that CHM is a systemic disease as rod- and 
needle- like crystals have been detected in peripheral blood lymphocytes with 
significant plasma fatty acid abnormalities.(48) Elevated plasmalogens (which are 
membrane glycerophospholipids that play a role in the structural properties of cell 
membranes, including signaling, fission, and fusion, and oxidative stress)(49), and 
nervonic acid (a monounsaturated omega-9 acid, important in the biosynthesis of 
neuronal myelin, and found in sphingolipids in the white matter of the human 
brain)(50), were detected, however the impact in peripheral blood plasma is currently 
unknown. This crystal deposition is considered to be related to fatty acid 
dysregulation secondary to defects in REP1-related intracellular vesicular trafficking. 
A systemic treatment, such as PTC124, therefore has the potential to prevent 
multisystem crystalline inclusion deposition and normalize any lipid disequilibrium. 
Detailed longitudinal clinical phenotyping studies are underway for CHM to 
understand the natural history of the disease and identify the most suitable therapeutic 
window. Clinical trials with Ataluren™ are forthcoming and may provide a potential 
treatment for those patients with CHM, but also associated inherited retinal disorders.  
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Material and Methods 
 
The study protocol adhered to the tenets of the Declaration of Helsinki and received 
approval from the NRES Committee London-Riverside Ethics Committee 
(REC12/LO/0489). Written, informed consent was obtained from all participants prior 
to their inclusion in this study. Zebrafish (wildtype AB and chmru848) were bred and 
maintained in the University College London animal facility according to standard 
protocols and the guidelines of the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research.(51)  
 
Zebrafish husbandry 
 
Wildtype AB (wt) and chmru848 embryos were generated by natural pair-wise matings 
of identified heterozygous carriers and raised at 28.5°C on a 14 h light/10 h dark cycle 
in a 100 mm2 petri dish containing aquarium water. The developmental stages are 
given in hours/days post-fertilisation (hpf/dpf), according to morphological 
criteria.(52)  
 
Cell culture of fibroblasts from skin biopsies 
 
A 5 mm punch skin biopsy was obtained from a 25 year old CHM patient (genotype 
confirmed p.Y42X [UAG] in exon 3) and an age-matched healthy male control under 
local anaesthetic. The biopsies were sectioned into smaller (1 mm) pieces using sterile 
scalpel blades and placed into a 6-well plate. The tissue was exposed to a minimal 
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amount of fibroblast growth media (DMEM, 10% foetal calf serum, 1 mM non-
essential amino acids, 1 mM GlutaMAXTM and penicillin–streptomycin, Life 
Technologies, Germany), overlaid with a sterile coverslip overnight and incubated at 
37°C in 5% CO2 in a humidified incubator. The following day 2 ml of fresh medium 
was added. The tissue was cultured until sufficient fibroblast outgrowth had occurred 
(~4 weeks) for further passage of cells. Fibroblast cells were washed in PBS, 
dissociated using TrypLETM Express (Life Technologies, Germany) and re-plated at a 
split ratio of 1:3. For maintenance, the media was replaced every 2-3 days and cells 
passaged when 80–90% confluent. Genomic DNA was extracted from fibroblast cells 
using the GeneEuteTM Mammalian Genomic DNA miniprep Kit (Sigma) and used in 
direct sequencing to re-confirm the CHM mutation.  
 
Drug efficacy 
 
Dechorionated wt embryos at 10 hpf were treated with test compounds, range from 
0.025-­‐40 µM; PTC124 (SelleckChem), PTC-414 (PTC Therapeutics Inc.) and 
gentamicin (Sigma, solution of 50 mg/mL in deionized water, liquid, sterile-filtered, 
BioReagent). Drugs were directly added to the aquaria water and embryos were raised 
until 6 dpf. For each treatment, 30 embryos were used and three independent 
experiments were performed. Outcomes were based on mortality and tolerability 
effects including behavioural and morphological defects at 6 dpf. Embryos surviving 
to 6 dpf with no signs of toxicity were prepared for histological analysis of the retina, 
ototoxicity studies (through neuromast survival and immunostaining) and renal 
function assays to determine tolerability. 
 
Levels of PTC124 and PTC-414 were measured in wt embryos at day 1, 3 and 6 post 
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single dose of 10 µM PTC124 and 2 µM of PTC-414 at 10 hpf to measure the 
concentration of compound within the whole embryo. Twenty embryos per group 
were analysed; three independent experiments performed. Embryos were 
homogenized and then mixed with acetonitrile-methanol mixture containing an 
internal standard that is a close analog of the test compounds. The samples were 
centrifuged and the supernatant was collected and quantified using electro-spray 
liquid chromatography-tandem mass spectrometry (LC-MS/MS).  
 
Fibroblasts were seeded at 600,000 cells per well of a six-well plate (Fisher Scientific, 
UK) and allowed to adhere for 24 hours. Cells were subsequently dosed twice over 24 
hours with gentamicin, PTC124 and PTC-414 (concentration range from 50-400 µM, 
30-60 µM and 50-80 µM, respectively) in DMEM + 10% FBS in the absence of any 
antibiotics. Compound was added to cells at 24 hours after seeding, and again after a 
further 8 hours. Cells were sampled 24 hours after the initial compound addition. 
 
PTC124 and PTC-414 survival studies 
 
The chmru848 mutant embryos were dechorionated at 10 hpf and treated with either 10 
µM of PTC124, 2 µM of PTC-414, 10 µM of gentamicin as a positive control or kept 
in control (drug-free) aquaria water. Survival of mutant larvae was recorded in days, 
n=50 for each treatment group. Further experiments using 5 and 15 µM of PTC124 
were tested on chmru848 embryos to confirm that the optimum dose for this study was 
10 µM on the basis of initial survival experiments. chmru848 embryos were also dosed 
with 10 µM PTC124 and 2 µM PTC-414 at 3 dpf and their survival observed.  
 
Retinal histology and morphological studies 
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At 6 and 10 dpf, embryos from each treatment group were collected and fixed in 4% 
paraformaldehyde (PFA) overnight at 4ºC. They were dehydrated through a graded 
ethanol series and then embedded in JB-4TM plastic resin (Polysciences/Sigma) 
according to the manufacturer’s instructions.(53) A Leica 2065 microtome was used 
to cut 7 µm sections, which were mounted on Polytetrafluoroethylene (PTFE) multi-
well printed microscope slides (EMS), stained with 1% Toluidine Blue and sealed 
with DPX mountant (Fisher) and 20 x 50 mm cover glass (VWR). Retinal histology 
was imaged using a Leica DMRB with Jenoptik D-07739 Optical System and 
wholemount images for morphological analysis were taken with a Nikon SMZ-1500 
stereo microscope with Nikon Digital Sight DS-Fi2 system. 
 
TUNEL assay 
 
Five embryos at 6 dpf from each treatment group were collected and fixed in 4% 
paraformaldehyde (PFA) overnight at 4ºC. The embryos were then cryoprotected in 
30% sucrose for 4 hours and embedded in Tissue-Tek® OCTTM and frozen on dry ice. 
Retinal sections were cut at 12 µm thickness using a Leica CM1850 Cryostat and 
mounted on Superfrost Plus slides. Following the manufacturer’s instructions, the 
ApopTag® Fluorescein In Situ Apoptosis Detection Kit (Millipore) was used to detect 
levels of apoptotic cell death. Sections were counterstained and sealed with Prolong® 
Diamond Antifade Mountant + DAPI (Life Technologies). Levels of fluorescence 
from apoptotic cell death were imaged using a Zeiss LSM510 upright confocal 
microscope, stacked images were analysed using ImageJ. 
 
Dihydroethidium staining 
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Levels of oxidative stress, generated through the presence of superoxide in the 
cytoplasm of cells, were detected in the eyes of live embryos using dihydroethidium 
(DHE, Life Technologies).(54) Five embryos at 6 dpf from each treatment group were 
incubated at 37°C for 5 min in 3 µM DHE. The embryos were washed twice with 
sterile water and then orientated and mounted in methylcellulose on multi-well 
microscope slides. Levels of red fluorescence present in the whole eye due to the 
oxidation of DHE was imaged using a Zeiss LSM510 upright confocal microscope, 
stacked images were analysed using ImageJ. 
 
Neuromast hair cell staining for ototoxicity 
 
Five wt embryos at 6 dpf from each treatment group were collected and incubated in 
200 µM 4-(4-diethylaminostyryl)-N-methylpyridinium iodide (4-Di-2-Asp, Sigma) 
for 1 minute at room temperature. The embryos were then orientated and mounted in 
methyl cellulose on self-made multiwell microscope slides and fluorescent signal 
from neuromasts was imaged using a Zeiss LSM510 upright confocal microscope and 
analysed using a modified neuromast scoring system.(7, 55) Zebrafish larvae have 19 
head neuromasts on each side that contribute to the lateral line system and were used 
as a scoring template for neuromast hair cell survival in n=5 per treatment group (Fig. 
2C). Individual neuromasts were scored as having normal 4-Di-2-Asp staining 
indicating hair cells are present (score = 2), reduced staining (score = 1), or absent 
staining (score = 0). Total neuromast scores were measured only the left side of each 
fish. The maximum score possible was 38 (19 multiplied by the high score of 2), 
which indicates normal staining of each neuromast.  
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To assess more detailed information about the number of hair cells present in an 
individual neuromast, embryos at 6 dpf were blocked in PBS with 1% Triton-X and 
20% normal goat serum (ngs) (both Sigma) for 4 hours at room temperature and then 
underwent wholemount immunostaining with anti-acetylated tubulin (Sigma) diluted 
1:500 in PBS with 0.5% Triton-X and 1% normal goat serum (ngs) overnight at 4°C. 
Embryos were then incubated for 1 hour at room temperature with Alexa Fluor® 488 
secondary antibody (Life Technologies)  diluted 1:10000 in PBS with 0.5% Triton-X 
and 1% ngs and then counterstained with Alexa Fluor® 647 Phalloidin (Life 
Technologies) diluted 1:10 in PBS with 0.5% Triton-X and 1% ngs. The embryos 
were then orientated and mounted in 1% agarose on self-made multiwell microscope 
slides and sealed using DPX mountant (Fisher) with 20 x 50 mm cover glass (VWR). 
Fluorescent hair cells were visualized using Zeiss LSM710 AxioImage M.1 upright 
confocal microscope. The number of hair cells in the opercular (OP) neuromast was 
counted as a further representation of drug toxicity.  
 
Fluorescent clearance assay for renal function  
 
Pronephric tubule filtration efficiency of 5 wt embryos from each treatment group 
was detected using pericardial microinjections of rhodamine dextran (Life 
technologies).(56) Using a Picospritzer III (Parker Instruments) and Narashige 
micromanipulator (Intracel), 1 nl of 5 mg/ml rhodamine-labelled 10 kDa dextran (Life 
Technologies) was injected into the pericardial cavity of live 3 dpf embryos. At 4 
hours and 24 hours post injection, the embryos were orientated and mounted on a 
multi-well microscope slide and fluorescent signal from the presence of rhodamine 
dextran was imaged using a Zeiss LSM510 upright confocal microscope and analysed 
using ImageJ. 
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RT-qPCR  
 
To determine the level of CHM/chm transcript, in order to relate this to the efficiency 
of the TRIDs treatment, total RNA was extracted from 6 dpf wt, chmru848 zebrafish, 
human CHM+/y and CHMY42X/y fibroblasts (TRID treated and untreated) using the 
RNeasy micro kit (Qiagen, UK) according to the manufacturer’s instructions. Using 
500 ng total RNA, cDNA was reverse transcribed using a Superscript III First-strand 
synthesis Supermix kit™ (Life Technologies). For quantitative real-time PCR 
amplifications, gene expression was quantified using SYBR Select™ fluorescent dye 
(Life Technologies) in triplicate reactions for each sample. All RT-qPCR primers and 
conditions are listed in Table 2. 
 
Zebrafish chm transcripts were amplified from exon 14 to exon 15 using intronic 
spanning primers with expression normalized to the geometric mean of β-actin, 
ribonucleoprotein L13a and ef1α internal housekeeping genes. Similarly, human 
CHM transcripts were amplified from exon 14 to exon 15 using intronic spanning 
primers and expression normalized to the geometric mean of human β-2-
microglobulin, β-tubulin and GAPDH internal housekeeping genes. The StepOne Plus 
RealTime PCR System (Life Technologies) was used and reactions analyzed using 
the Comparative CT experiment option in the StepOne software (Version 2.3).  
 
Western blotting  
 
Protein was isolated from 20 embryos per treatment condition at 6 dpf: wt, untreated 
chmru848 and mutants treated with 10 µM PTC124, 2 µM PTC-414 and 10 µM 
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gentamicin. Embryos were snap-frozen in liquid nitrogen and homogenized by 
sonication (3 x 10 sec, XL-2000 Qsonica LLC) with cold RIPA lysis buffer (Pierce) 
containing 1x Protease Inhibitor Cocktail (Sigma) and 1x Phosphatase Inhibitor 
Cocktail (Pierce).  
 
Patient CHM fibroblasts were seeded in DMEM containing 10% FBS with no 
antibiotics at 600,000 cells per well of a 6 well tissue culture plate and allowed to 
attach to the plate for 24h. Cells were subsequently treated with 50 µM gentamicin, 
40 µM PTC124 and 80 µM PTC-414 for a further 24h period before being collected 
for western blot. Cells were washed 1X ice-cold PBS and lysed on ice in a buffer 
containing: 10mM HEPES, 1% Triton, 150mM KCL, 1mM PMSF, 10ng/ml 
leupeptin, 1mM DTT, 50ng/ml aprotinin, 10mM NaF and 100µM sodium vanadate. 
Lysed cells were transferred to a microcentrifuge tube and incubated at 4°C for 30 
minutes. Cell debris was removed by centrifugation at 13,000 rpm for 30 minutes at 
4°C. 
 
Protein concentration was measured using the BCATM Protein Assay Kit (Pierce), a 
plate reader (Tecan Safire) and Magellan Software. For each sample, 30 µg of protein 
was boiled at 95°C for 5 minutes with 5 µl Nupage sample buffer and 2µl Nupage 
reducing agent (Life Technologies). Proteins were separated on an Any kDTM SDS–
polyacrylamide gel (BioRad) and transferred onto an Immun-BlotTM PVDF 
membrane (BioRad). The membrane was blocked overnight at 4ºC in blocking 
solution [5% dry milk, PBS/0.4% Tween (PBST)], washed five times in PBST and 
then incubated for 2 hours at room temperature with 1:1000 primary anti-Rep J905 
antibody for the zebrafish extract,(6) and 1:500 2F1 antibody (Millipore) for the 
human fibroblasts.(54) Following five washes in PBST, the membrane was incubated 
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with 1:10 000 secondary anti-rabbit IgG HRP conjugate (Sigma) in 1% milk-PBST 
for 1 hour at room temperature. The membrane was washed five times in PBST 
before chemiluminescent detection using the ECLTM Prime Western Blotting 
Detection Kit (GE Healthcare) and the ChemiDoc MP Imaging system (Biorad). 
Using RestoreTM Western Blot Stripping Buffer (Pierce), the membrane was stripped 
and re-probed with 1:5000 polyclonal anti-β-actin antibody (Sigma) as a loading 
control for both zebrafish and human fibroblasts. ImageLab software (BioRad) was 
used to determine the relative abundance of REP1/rep1 protein compared with 
corresponding levels of control protein expression. Three independent experiments 
were performed to determine the mean protein expression. 
 
In vitro prenylation assay  
 
Twelve embryos per treatment condition at 6 dpf were used: wt, untreated chmru848 
and treated chmru848 with 10 µM PTC124, 2 µM PTC-414 or 10 µM gentamicin. 
Embryos were snap-frozen in liquid nitrogen and then homogenized in cold, degassed 
buffer (25 mM HEPES pH 7.2, 50 mM NaCl, 1 mM MgCl2, 2mM DTE, 1x Protease 
Inhibitor Cocktail) by sonication (3x 10s, XL-2000 Qsonica LLC). Nuclei were 
pelleted by centrifugation at 1500 g for 5 min at 4°C, then the post nuclear 
supernatant was collected and centrifuged at 100,000g for 1 h at 4°C using a TLA45 
rotor in a Optima MAX-E Beckman Coulter to obtain cytosolic protein extracts.  
 
Human CHM fibroblasts, untreated and treated with an increasing concentration of 
gentamicin (up to 400 µM), PTC124 (up to 50 µM) or PTC-414 (up to 80 µM), 
cultured in a 6-well plate were washed in cold PBS, scraped in PBS containing anti-
proteases, pelleted and resuspended in cold, degassed prenylation/lysis buffer 
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prepared fresh as described previously.(57) Cells were incubated 15 minutes on ice 
and then sonicated 3 times for 45 s at 40 Hz. The cells were then centrifuged for 5 
min at 1500 g at 4°C, the supernatant collected and further centrifuged for 1 hr at 
50,000 g at 4°C on an Optima MAX-TL ultracentrifuge (Beckman, France).  
 
An in vitro prenylation assay was performed on the freshly prepared lysate using 5 
µM biotin-labelled geranyl pyrophosphate (B-GPP) (Jena Bioscience, Germany) as a 
prenyl group donor, 0.5 µM recombinant REP1 (Jena Bioscience, Germany), 0.5 µM 
recombinant Rab geranylgeranyl transferase (RGGT; Jena Bioscience, Germany) and 
20 µM GDP in prenylation/lysis buffer at 37°C for 1 h.(13, 57, 58) The prenylation 
reaction was stopped with 6x SDS loading buffer, boiled at 95°C for 5 min and biotin 
incorporation analysed by western blot. The membrane was incubated with 1:3000 
HRP-conjugated streptavidin (Jackson ImmunoResearch, Cambridge, Great Britain) 
and 1:2000 goat anti GAPDH (Everest Biotech Ltd., UK). Detection was performed 
using the ChemiDoc MP Imaging system (Biorad). The amount of biotinylated Rab 
proteins was then quantified by scanning densitometry using the appropriate software 
package (ImageJ) and expressed as a function of the GAPDH signal. To allow relative 
comparisons, the biotinylated Rab population in the untreated CHM samples was set 
to 100%. Three independent experiments were performed to determine the mean 
prenylation function following drug treatment. 
 
Statistical Analysis 
 
All results are expressed as mean ± SEM, unless specified. As sample sizes are small, 
non-parametric tests were used. Differences between control untreated and each 
treatment group were assessed by pair-wise comparisons using the Mann-Whitney 
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test or the Kruskal–Wallis analysis of variance if more than 2 groups were 
investigated, followed by Dunn’s multiple comparison test where appropriate. A p-
value of <0.01 was considered statistically significant.  
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Legends 
 
Figure 1. Dose–response studies. (A) wt embryos dosed at 10 hpf with gentamicin 
(solid line), PTC124 (dashed line) or PTC-414 (dotted line). Percentage survival at 6 
dpf was determined for each treatment group, n=3 (30 embryos/group), mean ± SEM. 
Error bars smaller than the symbol are not visible. (B) Coronal retinal sections and 
wholemount morphology of wt larvae at 6 dpf with or without treatment with 10 µM 
gentamicin, 10 µM PTC124 or 2 µM PTC-414. RPE, retinal pigment epithelium; 
INL, inner nuclear layer; L, lens; GCL, ganglion cell layer; ONL, outer nuclear layer; 
ON, optic nerve. (C) Levels of drug in wt fish after a single dose at 10 hpf with 10 
µM PTC124 (dashed line) or 2 µM PTC-414 (dotted line) compared to undosed fish 
(solid black line) at day 1, 3 and 6 post administration.  
 
Figure 2. Renal- and oto-toxicity studies. (A) Fluorescent image of a wt embryo with 
or without treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ PTC124) or 2 
µM PTC-414 (+ PTC-414), following injection of rhodamine dextran into the heart 
(white arrow) at 3 dpf. Top row is 4 hours post injection (t = 4 hr) and bottom row is 
24 hours later (t = 24 hr); (B) Graph quantifying the percentage of original rhodamine 
dextran fluorescence remaining in the circulation at 24 h after injection (n=5 embryos 
for each group, mean ± SEM). (C) Neuromast survival from wt larvae at 6 dpf with or 
without treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ PTC124) or 2 µM 
PTC-414 (+ PTC-414) quantified with 4-Di-2-Asp scores, n=5 embryos for each 
group, mean ± SD). The scoring template highlights the positions of the 19 head 
neuromasts. OP, opercular neuromast. 4-Di-2-Asp score for gentamicin treated fish 
was significantly decreased (*p<0.01) compared to undosed and PTC-derivatives. (D) 
Lateral line neuromasts in the head region of wt larvae at 6 dpf with or without 
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treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ PTC124) or 2 µM PTC-
414 (+ PTC-414) stained with 4-Di-2-Asp (top row). The opercular (OP) neuromast 
was imaged as a representative from each corresponding fixed 6 dpf wt larva (bottom 
row) containing double labeled hair cells with anti-acetylated tubulin (green, 
kinocilia) and phalloidin (purple, stereocilia bundles).  
 
Figure 3. Survival studies. (A) Mean survival of chmru848 mutant embryos (chm) with 
or without treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ PTC124) or 2 
µM PTC-414 (+ PTC-414), n=50 for each group, mean ± SEM. Statistical analysis of 
the data by pair-wise comparisons between the control untreated mutants and each 
treatment group was performed using the Mann–Whitney test, *P<0.01. (B) Mean 
survival of chm embryos with or without treatment with 5, 10 and 15 µM PTC124 at 
10 hpf, or 10 µM PTC124 at 3 dpf (n=30 for each group, mean ± SEM). (C) Gross 
wholemount morphology of 6 dpf wt, chm untreated and treated with 10 µM 
gentamicin (+G), 10 µM PTC124 (+ PTC124) or 2 µM PTC-414 (+ PTC-414) 
embryos showing overall improvement in systemic appearance in treated fish. (D) 
Mean eye diameter (µm) and (E) mean body length (mm) of chm mutant embryos 
with or without treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ PTC124) 
or 2 µM PTC-414 (+ PTC-414) at 6 dpf (n=5 for each group, mean ± SEM). Treated 
mutants showed a larger eye size and body length (*P<0.01) compared to untreated 
chm embryos. 
 
Figure 4. Retinal phenotyping of chmru848 embryos treated with TRIDs. (A) Top row 
shows coronal retinal sections stained with 1% toluidine blue through wt and chm 6 
dpf eyes with or without treatment with 10 µM gentamicin (+G), 10 µM PTC124 (+ 
PTC124) or 2 µM PTC-414 (+ PTC-414); middle row shows corresponding TUNEL 
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staining at 6 dpf with undosed chm mutants displaying widespread TUNEL staining 
compared to wt and treated chm embryos; bottom row shows stacked confocal images 
of corresponding whole eyes with dihydroethidium (DHE) staining highlighting levels 
of oxidative stress. (B) Mean TUNEL fluorescence/eye ± SEM derived from n=5 
embryos for each group, was analysed using ImageJ. All treated chm mutants showed 
significantly less cell death than untreated chm embryos (*P>0.01). (C) Mean DHE 
fluorescence/eye ± SEM derived from n=5 embryos for each group, was analysed 
using ImageJ. All three TRIDs reduce the level of oxidative stress in the eye 
compared to undosed chm mutants (*P>0.01), but PTC-derived drugs were able to 
normalize to wt levels. (D) Coronal retinal sections through 10 dpf wt and chm eyes 
treated with 10 µM PTC124 (+ PTC124) or 2 µM PTC-414 (+ PTC-414). Red 
arrowheads point to areas of RPE atrophy and black arrowheads point to RPE 
hypertrophy. All scale bars represent 100 µm.  
 
Figure 5. mRNA, protein and prenylation studies. (A) Real-time qRT-PCR to detect 
endogenous full-length mRNA transcripts in human CHMY42X/y fibroblasts (black 
bars) and zebrafish chmru848 embryos (grey bars) at 6 dpf (CHM/chm) with or without 
treatment with 40 µM/10 µM PTC124 (+ PTC124) or 80 µM/2 µM PTC-414 (+ PTC-
414) in fibroblasts/zebrafish, respectively, relative to the geometric mean of three 
internal housekeeping genes (for human β-2-microglobulin, β-tubulin and GAPDH; 
and for zebrafish β-actin, ribonucleoprotein L13a and ef1α). Values are plotted as the 
mean ± SEM, n=3. PTC124 significantly increased chm mRNA levels compared with 
untreated mutant zebrafish (p<0.01). This change was not reflected in human CHM 
fibroblasts. (B) Western blot analysis of rep1 protein expression. Total zebrafish 
protein lysates from twenty 6 dpf wt (1), undosed chm (2) and mutants treated with 10 
µM gentamicin (3), 10 µM PTC124 (4) or 2 µM PTC-414 (5), and positive control 
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Hela cells (6). The blot was stripped and reprobed with anti β-actin as a loading 
control for samples. Quantification of rep1 protein expression relative to β-actin 
expression using ImageJ software, represented as mean ± SEM, n=3 independent 
blots). Dotted line highlights level of maternal rep contribution in untreated chm 
embryos. Increased rep1 protein levels (above the line) were found in all treatment 
groups representing TRID efficacy. (C) In vitro prenylation assay showing functional 
rep1 activity in chm mutants treated with TRIDs. Cytosolic extracts from twelve 6 dpf 
wt (1), undosed chm (2), and mutants treated with 10 µM PTC124 (3), 2 µM PTC-414 
(4), or 10 µM gentamicin (5) were subjected to in vitro prenylation assay using a 
biotinylated prenyl donor followed by western blot analysis. High signal of 
incorporated biotin for the undosed chm embryos, compared to negligible signal and 
therefore no accumulation of unprenylated rabs in wt and PTC124 treated embryos, 
and reduced signal in PTC-414 and gentamicin treatment groups. This result was seen 
in three independent experimental repeats. The blot was stripped and reprobed with 
anti β-actin as a loading control for samples.  
 
Figure 6. REP1 functional rescue in human CHM fibroblasts. (A) Western blot 
analysis of REP1 protein expression showing no detection in untreated CHMY42X/y 
fibroblasts (1), or those treated with 50 µM gentamicin (2), 40 µM PTC124 (3) or 80 
µM PTC-414 (4). A positive REP1 band was detected in WT fibroblasts (5) and 
positive control Hela cells (6). The blot was stripped and reprobed with anti-GAPDH 
as a loading control for samples. This result was seen in three independent 
experiments. (B) In vitro prenylation assay showing functional REP1 activity in 
CHMY42X/y fibroblasts treated with a range of gentamicin. An unprenylated Rab pool 
was detected in untreated CHM fibroblasts (1). Reducing signal was detected for 
CHM fibroblasts treated with 50 µM  (2), 100 µM (3), and 400 µM gentamicin (4). 
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No signal and therefore no accumulation of unprenylated Rabs in the wildtype control 
fibroblasts (5). The blot was stripped and reprobed with anti-GAPDH as a loading 
control for samples. Semi-quantification of the biotinylated Rab pool, after 
normalization with GAPDH, confirms a significantly lower (*P<0.01) relative 
quantity of biotinylated Rabs in the CHM fibroblasts treated with 50 and 100 µM 
gentamicin compared to undosed and 400 µM treated cells. Data represented as mean 
± SEM, n=3 independent assays. (C) In vitro prenylation assay showing functional 
REP1 activity in CHMY42X/y fibroblasts treated with PTC124. An unprenylated Rab 
pool was detected in untreated CHM fibroblasts (1) and CHM fibroblasts treated with 
30 µM PTC124 (2). Reducing signal was detected for CHM fibroblasts treated with 
40 µM PTC124 (3) and 50 µM PTC124 (4), with no signal and therefore no 
accumulation of unprenylated Rabs in the wildtype control fibroblasts (5).   The blot 
was stripped and reprobed with anti-GAPDH as a loading control for samples. Semi-
quantification of the biotinylated Rab pool, after normalization with GAPDH, 
confirms a significantly lower (*P<0.01) relative quantity of biotinylated Rabs in the 
CHM fibroblasts treated with ≥40 µM PTC124 compared to undosed and <40 µM 
treated cells. Data represented as mean ± SEM, n=3 independent assays. (D) In vitro 
prenylation assay showing functional REP1 activity in CHMY42X/y fibroblasts treated 
with PTC-414. An unprenylated Rab pool was detected in undosed CHM fibroblasts 
(1) and CHM fibroblasts treated with 50 µM PTC-414 (2). Reducing signal was 
detected for CHM fibroblasts treated with 60 µM PTC-414 (3), 70 µM PTC-414 (4), 
and 80 µM PTC-414 (5), with minimal signal in the wildtype control fibroblasts (6). 
The blot was stripped and reprobed with anti-GAPDH as a loading control for 
samples. Semi-quantification of the biotinylated Rab pool, after normalization with 
GAPDH, confirms a significantly lower (*P<0.01) relative quantity of biotinylated 
Rabs in the CHM fibroblasts treated with ≥60 µM PTC-414 compared to undosed and 
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<50 µM treated cells. Data represented as mean ± SEM, n=3. M, Biorad Precision 
Plus Dual Colour marker for all blots.  
 
 
	   46	  
 
Table 1. Characteristics of PTC124 and PTC-414 
Activity Compound 
 PTC124 PTC-414 
UGA readthrough (fold over DMSO^)  
in luciferase reporter assay# 
4.1 fold 6.3 fold 
UAA readthrough (fold over DMSO^)  
in luciferase reporter assay# 
1.1 fold 2.4 fold 
UAG readthrough (fold over DMSO^)  
in luciferase reporter assay# 
1.0 fold 2.0 fold 
Activity in human liver microsome assay to assess in 
vitro drug metabolism (% lost after 1 hr incubation) 
<10% 
metabolised 
12% 
metabolised 
Mouse plasma exposure (10 mg/kg oral dose)♦ 
1 hr after 10 mg/kg oral dose of compound 
3 hr after 10 mg/kg oral dose of compound 
6 hr after 10 mg/kg oral dose of compound 
 
0.87 µg/ml 
0.17 µg/ml 
0.04 µg/ml 
 
0.41 µg/ml  
0.22 µg/ml  
0.19 µg/ml 
*CC50 in LLC-PK1 (kidney proximal tubule) cells >100 µM >100 µM 
 
^DMSO: dimethyl sulfoxide used as solvent 
#Luciferase reporter containing indicated stop codon at amino acid position 190 as 
described previously.(10) 
♦Plasma concentration at each time interval after a 10 mg/kg dose of compound was 
quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
*CC50 = cytotoxic effects of compounds in LLC-PK1 cells were expressed as the 50% 
cytostatic concentration (CC50), defined as the concentration required to reduce cell 
growth by 50% 
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Table 2. Genotyping PCR and qRT-PCR primers with conditions for the amplification 
of zebrafish chm, human CHM and housekeeping genes 
Gene Primers  Annealing 
(°C) 
Size 
(bp) 
Zebrafish chm forward primer 
ACCATGGGCCGCCACCATGGCTGCGGAGGATCTCCCGTCT 
Zebrafish chm reverse primer 
TCCATGGGCGCAGAATCTTCATTCTCTTC 
60 496 
Human CHM forward primer  
ACAAACTCCAAGCAGCGATCCA 
Human CHM reverse primer  
TGCTCTGGAACACGGAACCTG 
57 370 
Zebrafish chm qPCR forward primer 
TGGACTGGGCAGCGACTACT 
Zebrafish chm qPCR forward primer 
CTTCAGCCTGTGGAGCGTCA 
60 134 
Zebrafish β-actin qPCR forward primer 
TGTACCCTGGCATTGCTGAC 
Zebrafish β-actin qPCR reverse primer 
TGGAAGGTGGACAGGGAGGC 
60 144 
Zebrafish ribonucleoprotein L13a qPCR forward primer 
TCTGGAGGACTGTAAGAGGTATGC 
Zebrafish ribonucleoprotein L13a qPCR reverse primer 
AGACGCACAATCTTGAGAGCAG 
60 148 
Zebrafish ef1α qPCR forward primer 
CTGGAGGCCAGCTCAAACAT 
Zebrafish ef1α qPCR reverse primer 
ATCAAGAAGAGTAGTACCGCTAGCATTAC 
60 87 
Human CHM qPCR forward primer 
TGGACTGGGCAGCGACTACT 
Human CHM qPCR reverse primer 
CTTCAGCCTGTGGAGCGTCA 
60 163 
Human β2-microglobulin forward primer 
TGTACCCTGGCATTGCTGAC 
Human β2- microglobulin reverse primer 
TGGAAGGTGGACAGGGAGGC 
60 97 
Human β-tubulin forward primer 
TCTGGAGGACTGTAAGAGGTATGC 
Human β-tubulin reverse primer 
AGACGCACAATCTTGAGAGCAG 
60 119 
Human GAPDH forward primer 
CTGGAGGCCAGCTCAAACAT 
Human GAPDH reverse primer 
ATCAAGAAGAGTAGTACCGCTAGCATTAC 
60 104 
 
 
 
